Department of Hematology Oncology, The People's Hospital of NanChuan District, ChongQing, People's Republic of China.
Hematology. 2021 Dec;26(1):663-669. doi: 10.1080/16078454.2021.1967256.
Infections in ruxolitinib-treated myeloproliferative neoplasm (MPN) patients were reported frequently. This work aimed to systematically estimate the risk of infection associated with ruxolitinib in MPN patients.
The PUBMED, CNKI, EMBASE, Cochrane and CBM databases were searched to identify all related studies. Odds ratio (OR) and 95% confidence interval (CI) were used to express the difference between groups. was calculated to evaluate heterogeneity. Revman software was used to conduct the analysis.
Eleven randomized control trials were included in this analysis. The risk of overall infections was not different at the early stage of ruxolitinib use (OR, 95%CI: 1.23, [0.91, 1.67]). In the extension phase, overall infection was significantly lower in patients receiving ruxolitinib (OR, 95%CI: 0.53, [0.36, 0.79]). Herpes zoster infection was at higher risk both at early stage and in the extension phase (OR, 95%CI: 7.39, [1.33, 41.07]), (OR, 95%CI: 5.23, [1.46, 18.79]), respectively.
Our study suggested that ruxolitinib increased the risk of herpes zoster infection. However, current studies were not enough to estimate the effects of ruxolitinib on the risk of overall infection in patients with myeloproliferative neoplasm.
已有报道称，接受鲁索利替尼治疗的骨髓增殖性肿瘤（MPN）患者常发生感染。本研究旨在系统评估鲁索利替尼治疗 MPN 患者相关感染的风险。
检索 PUBMED、CNKI、EMBASE、Cochrane 和 CBM 数据库，以确定所有相关研究。采用比值比（OR）及其 95%置信区间（CI）表示组间差异。采用 检验评估异质性。采用 RevMan 软件进行分析。
共纳入 11 项随机对照试验。鲁索利替尼早期使用时，总体感染风险无差异（OR，95%CI：1.23，[0.91，1.67]）。在扩展阶段，接受鲁索利替尼治疗的患者总体感染显著降低（OR，95%CI：0.53，[0.36，0.79]）。疱疹性感染在早期和扩展阶段的风险均较高（OR，95%CI：7.39，[1.33，41.07]），（OR，95%CI：5.23，[1.46，18.79]）。
本研究表明，鲁索利替尼增加了疱疹性感染的风险。然而，目前的研究还不足以评估鲁索利替尼对骨髓增殖性肿瘤患者总体感染风险的影响。
